Oral tacrolimus (FK 506) in refractory paediatric ulcerative colitis: authors’ reply

Maculopathy Associated with Tacrolimus (FK 506)

A 63-year-old man with a history of liver transplantation presented to our clinic complaining of visual disturbance. He had been receiving tacrolimus (FK 506) for 30 months (6 mg/day for 2 years and 3 mg/day for 6 months); he reported that the visual disturbance began while taking tacrolimus. A full ophthalmologic examination and electrophysiologic and imaging studies were performed. The best c...

Tacrolimus ( FK 506 ) and the Pharmaceuticall Academid Regulatory Gauntlet

• The pivotal Issue of transplant rejection diagnosis and management Is design, conduct, and analysis of clinical trials. The historical experience with clinical trials of major immunosuppressive drugs (cyclosporine and especially tacrollmus) Is examined in this article. Cyclosporlne was a turning point In transplantation, providing an extraordinary Improvement over previous therapies. Addition...

Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.

Cyclosporin for refractory ulcerative colitis.

Approximately 15% of patients with ulcerative colitis will have a severe attack requiring hospitalisation for intravenous steroids at some stage in their illness. Sixty per cent of patients treated with corticosteroids will be symptom free by the end of five days, 15% will have significant improvement, and 25% will not improve. Those who fail to improve may be treated with intravenous cyclospor...

Tacrolimus for the Treatment of Ulcerative Colitis

Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of tacrolimus in UC patients. These studies showed that tacrolimus has excellent short-term efficacy in corticosteroid-refractory patients, with the rates of clinical respons...